Novavax Inc (NVAX) reports increased product sales and a strong cash position, while revising revenue guidance and navigating ...

BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...

TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...

Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good morning and welcome to Novavax' ...

Novavax (NASDAQ:NVAX) shares lost ~12% in the premarket on Tuesday after the Gaithersburg, MD-based biotech, with its Q3 2024 ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

Analysts are estimating that Novavax will report an earnings per share (EPS) of $-0.87. Anticipation surrounds Novavax's ...

GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Novavax Inc. (NVAX) on Tuesday reported a loss of $121.3 million in its third quarter. On a per-share basis, the Gaithersburg, Maryland-based company ...